PURPOSE: To assess patterns of H&N IMRT practice with particular emphasis on elective target delineation. MATERIALS AND METHODS: Twenty institutions with established H&N IMRT expertise were solicited to design clinical target volumes for the identical H&N cancer case. To limit contouring variability, a primary tonsil GTV and ipsilateral level II node were pre-contoured. Participants were asked to accept this GTV, and contour their recommended CTV and PTV. Dose prescriptions, contouring time, and recommendations regarding chemotherapy were solicited. RESULTS: All 20 institutions responded. Remarkable heterogeneity in H&N IMRT design and practice was identified. Seventeen of 20 centers recommended treatment of bilateral necks whereas 3/20 recommended treatment of the ipsilateral neck only. The average CTV volume was 250 cm(3) (range 37-676 cm(3)). Although there was high concordance in coverage of ipsilateral neck levels II and III, substantial variation was identified for levels I, V, and the contralateral neck. Average CTV expansion was 4.1mm (range 0-15 mm). Eight of 20 centers recommended chemotherapy (cisplatin), whereas 12/20 recommended radiation alone. Responders prescribed on average 69 and 68 Gy to the tumor and metastatic node GTV, respectively. Average H&N target volume contouring time was 102.5 min (range 60-210 min). CONCLUSION: This study identifies substantial heterogeneity in H&N IMRT target definition, prescription, neck treatment, and use of chemotherapy among practitioners with established H&N IMRT expertise. These data suggest that continued efforts to standardize and simplify the H&N IMRT process are desirable for the safe and effective global advancement of H&N IMRT practice.
PURPOSE: To assess patterns of H&N IMRT practice with particular emphasis on elective target delineation. MATERIALS AND METHODS: Twenty institutions with established H&N IMRT expertise were solicited to design clinical target volumes for the identical H&N cancer case. To limit contouring variability, a primary tonsil GTV and ipsilateral level II node were pre-contoured. Participants were asked to accept this GTV, and contour their recommended CTV and PTV. Dose prescriptions, contouring time, and recommendations regarding chemotherapy were solicited. RESULTS: All 20 institutions responded. Remarkable heterogeneity in H&N IMRT design and practice was identified. Seventeen of 20 centers recommended treatment of bilateral necks whereas 3/20 recommended treatment of the ipsilateral neck only. The average CTV volume was 250 cm(3) (range 37-676 cm(3)). Although there was high concordance in coverage of ipsilateral neck levels II and III, substantial variation was identified for levels I, V, and the contralateral neck. Average CTV expansion was 4.1mm (range 0-15 mm). Eight of 20 centers recommended chemotherapy (cisplatin), whereas 12/20 recommended radiation alone. Responders prescribed on average 69 and 68 Gy to the tumor and metastatic node GTV, respectively. Average H&N target volume contouring time was 102.5 min (range 60-210 min). CONCLUSION: This study identifies substantial heterogeneity in H&N IMRT target definition, prescription, neck treatment, and use of chemotherapy among practitioners with established H&N IMRT expertise. These data suggest that continued efforts to standardize and simplify the H&N IMRT process are desirable for the safe and effective global advancement of H&N IMRT practice.
Authors: Gordon O Schoenfeld; Robert J Amdur; Christopher G Morris; Jonathan G Li; Russell W Hinerman; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: K S Chao; J O Deasy; J Markman; J Haynie; C A Perez; J A Purdy; D A Low Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-15 Impact factor: 7.038
Authors: B O'Sullivan; P Warde; B Grice; C Goh; D Payne; F F Liu; J Waldron; A Bayley; J Irish; P Gullane; B Cummings Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: C Wesley Hodge; Søren M Bentzen; Gordon Wong; Karen L Palazzi-Churas; Peg A Wiederholt; Vinai Gondi; Gregory M Richards; Gregory K Hartig; Paul M Harari Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-15 Impact factor: 7.038
Authors: K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Christopher R Spencer; Hiram A Gay; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; Tanya M Wildes; Todd A DeWees; James S Lewis; Wade L Thorstad Journal: Cancer Date: 2014-08-20 Impact factor: 6.860
Authors: Musaddiq Awan; Jayashree Kalpathy-Cramer; G Brandon Gunn; Beth M Beadle; Adam S Garden; Jack Phan; Emma Holliday; William E Jones; Elizabeth Maani; Abhilasha Patel; Jehee Choi; Virginia Clyburn; Bundhit Tantiwongkosi; David I Rosenthal; Clifton D Fuller Journal: Pract Radiat Oncol Date: 2012-12-21
Authors: Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote Journal: J Clin Oncol Date: 2019-06-04 Impact factor: 44.544
Authors: Adam R Burr; Paul M Harari; Alyx M Haasl; Aaron M Wieland; Justine Y Bruce; Randall J Kimple; Gregory K Hartig; Timothy M McCulloch; Matthew E Witek Journal: Head Neck Date: 2020-02-14 Impact factor: 3.147
Authors: Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2014-12-08 Impact factor: 44.544